cancer).

Savoy’s technology is based on the company’s revolutionary discovery that TK1 is expressed on HCV-infected cells, HIV infected cells, and liver cancers, and is not found on the surface of any normal cell type. The company has developed a fully human monoclonal antibody that binds specifically to TK1 on the surface of liver cancer directly attributable to the Hepatitis C Virus, HCV, infected cells, HCV and HIV co-infected cells (HCV/HIV). The company has performed the preclinical testing required to demonstrate that our antibody binds to and kills cancerous cells while causing no harm to any normal cells or tissues in the body. This is a breakthrough in the war against cancer and opens the door to unique therapeutic applications using the antibody.